Healthcare providers: In this NEW educational activity familiarize yourself with strategies for preventing and managing potentially life-threatening adverse events associated with bispecific antibody therapy, including cytokine release syndrome (CRS), neurotoxicity, and infection. Start this activity today: https://ow.ly/HpK350SMIWa #Myeloma #MultipleMyeloma #HealthcareEducation #BispecificAntibodies
Multiple Myeloma Research Foundation - MMRF
Non-profit Organizations
Norwalk, Connecticut 14,132 followers
Accelerating a smarter, faster, cure for mutiple myeloma.
About us
We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients.
- Website
-
http://themmrf.org
External link for Multiple Myeloma Research Foundation - MMRF
- Industry
- Non-profit Organizations
- Company size
- 51-200 employees
- Headquarters
- Norwalk, Connecticut
- Type
- Nonprofit
- Founded
- 1998
Locations
-
Primary
383 Main Avenue
5th Floor
Norwalk, Connecticut 06851, US
Employees at Multiple Myeloma Research Foundation - MMRF
-
Pam Lewis
Leader in Fundraising, Patient Advocacy and Programming. Catalyst and Pied Piper.
-
Christopher Williams
-
Adriana Davis
Producer/Editor/Voice-Over Artist, Director
-
Lori Tauber Marcus
Experienced Board Director, Chair, Compensation Committee, Nominating Governance Committee, Audit Committee, Board Development Committee, Public…
Updates
-
Immunotherapies are powerful myeloma treatments that can provide durable remissions, but side effects are common. In our newest Myeloma Matters podcast episode, you’ll learn how to recognize and get through the main side effects of myeloma immunotherapy. Listen here: https://ow.ly/bTFe50SMITu #mmsm
Myeloma Matters Podcast | Immunotherapy Side Effects
https://www.youtube.com/
-
🎉 Congratulations to Dr. Hearn Cho on your well-deserved promotion to Clinical Professor of Medicine (Hematology and Medical Oncology) at Icahn School of Medicine at Mount Sinai!
-
-
On 7/30 the U.S. FDA announced approval of Johnson & Johnson Innovative Medicine’s Darzalex FasPro, as part of a 4-drug combination (including bortezomib, lenalidomide and dexamethasone) for newly diagnosed patients. #myeloma https://lnkd.in/e3wxqgXt Learn more about the Darzalex FasPro study. https://lnkd.in/e8AR67sJ
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
jnj.com
-
On Monday (8/5), MMRF Patient Navigator Grace Allison will be speaking at the local Oncology Nursing Society in Little Rock, Arkansas. At this dinner, she will share what’s new in multiple #myeloma. If you live in this area – register here: https://ow.ly/iayl50SOxHp
What’s New in Multiple Myeloma? A Chat with Grace Allison from MMRF
-
We’re thrilled to announce the Myeloma Investment Fund has announced a new investment in Envisagenics, an A.I.-driven biotechnology company. This partnership aims to advance RNA-based therapeutics, addressing critical unmet needs in multiple myeloma treatment. For more details, visit: https://lnkd.in/eKB7hVQn
Myeloma Investment Fund Invests in Envisagenics, A.I.-Driven Biotechnology Company - MMRF
https://themmrf.org
-
Healthcare professionals: Advance your knowledge and skills in managing bispecific antibody-associated adverse events. In our NEW #Myeloma Matters podcast episode, Dr. Jesus Berdeja, other experts, and patients share their perspectives on bispecific antibody therapy. Listen here: https://ow.ly/Pu3z50SKgm6
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
reachmd.com
-
In each podcast episode, fellow #myeloma patients share their experiences and perspectives on important topics, including: 🎧 Bone Health 🎧 Immunotherapy Side Effects 🎧 Maintenance Therapy 🎧 ASCT 🎧 Newly Diagnosed Multiple Myeloma 🎧 & more! Listen now: https://ow.ly/ujpW50SKfS3
-
-
Health care professionals: In this roundtable, experts discuss the diagnosis of multiple #myeloma in primary care. A quick and accurate diagnosis is paramount. Earn your CME credit today: https://ow.ly/TtkF50SGh35
Multiple Myeloma and its Precursors in Primary Care | myCME
mycme.com
-
We’re here for you every day, week, and month ❤️. We offer educational resources and 1:1 support that help you along every step of your multiple myeloma journey. To find the support you need today, visit: https://ow.ly/1h4K50SGexi
-